To the content
2 . 2021

The use of pegvisomant in the complex treatment of acromegaly. Cases from practice

Abstract

The paper discusses rational schemes of pharmacotherapy for acromegaly and the place of pegvisomant in the complex drug treatment of patients with aggressive disease. The first domestic results of the use of pegvisomant, as well as cases from the clinical practice of pharmacotherapy of acromegaly, are presented.

Keywords:acromegaly, pituitary adenoma, drug therapy, growth hormone receptor antagonist, pegvisomant, analogues of somatostatin

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

For citation: Pronin E.V., Antsiferov M.B., Alekseeva T.M. The use of pegvisomant in the complex treatment of acromegaly. Cases from practice. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (2): 167-9. DOI: https://doi.org/10.33029/2304-9529-2021-10-2-167-169 (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Ametov Alexander S.
Honored Scientist of the Russian Federation, Doctor of Medical Sciences, Professor, Head of Subdepartment of Endocrinology, Head of the UNESCO Network Chair on the subject «Bioethics of diabetes as a global problem» of the Russian Medical Academy of Continuous Professional Education (Moscow)
Вскрытие

Journals of «GEOTAR-Media»